Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction
Margaret McEntegart, Margaret
European Heart Journal
Oxford University Press
MetadataShow full item record
Davenport, A., Ford, T., Corcoran, D., Padmanabhan, S., Aman, A., Rocchiccioli, P., Good, R., et al. (2020). Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. European Heart Journal https://doi.org/10.1093/eurheartj/ehz915
Background: Endothelin-1 (ET-1) is a potent vasoconstrictor peptide linked to vascular diseases through a common intronic gene enhancer [(rs9349379-G allele), chromosome 6 (PHACTR1/EDN1)]. We performed a multimodality investigation into the role of ET-1 and this gene variant in the pathogenesis of coronary microvascular dysfunction (CMD) in patients with symptoms and/or signs of ischaemia but no obstructive coronary artery disease (INOCA). Methods and Results: 391 angina patients were enrolled, 206 (53%) with obstructive CAD were excluded leaving 185 (47%) eligible. 109 (72%) of 151 subjects who underwent invasive testing had objective evidence of CMD (COVADIS criteria). rs9349379-G allele frequency was greater than in contemporary reference genome bank control subjects (allele frequency 46% (129/280 alleles) v 39% (5551/14380); P=0.013). The G allele was associated with higher plasma serum ET-1 (LS mean 1.59pg/mL v 1.28pg/mL; 95% CI 0.10 to 0.53; P=0.005). Patients with rs9349379-G allele had over double the odds of CMD (OR 2.33; 95% CI 1.10 – 4.96; P=0.027). Multimodality non-invasive testing confirmed the G allele was associated with linked impairments in myocardial perfusion on stress cardiac magnetic resonance imaging at 1.5 Tesla (N=107; GG 56%, AG 43%, AA 31%, P=0.042) and exercise testing (N=87; -3.0 units in Duke Exercise Treadmill Score; -5.8 to -0.1; P=0.045). ET-1 related vascular mechanisms were assessed ex vivo using wire myography with ETA receptor (ETA) antagonists including zibotentan. Subjects with rs9349379-G allele had preserved peripheral small vessel reactivity to ET-1 with high affinity of ETA antagonists. Zibotentan reversed ET-1-induced vasoconstriction independently of G allele status. Conclusion: We identify a novel genetic risk locus for coronary microvascular dysfunction. More research is needed however these findings implicate ET-1 dysregulation and support the possibility of precision medicine using genetics to target oral ETA antagonist therapy in patients with microvascular angina.
The Wellcome Trust 107715/Z/15/Z.
WELLCOME TRUST (107715/Z/15/Z)
Embargo Lift Date
External DOI: https://doi.org/10.1093/eurheartj/ehz915
This record's URL: https://www.repository.cam.ac.uk/handle/1810/302449
All rights reserved